Anticorps Monoclonal anti-NeutraControl VEGF165

NeutraControl VEGF165 Monoclonal Antibody for Non-Neutralization, ELISA

Hôte / Isotype

Mouse / IgG1

Réactivité testée

Humain

Applications

Non-Neutralization

Conjugaison

Non conjugué

CloneNo.

7E9F4

N° de cat : 69525-1-Ig

Synonymes

L VEGFA, MVCD1, Vascular permeability factor, VEGF, VEGF A, VEGFA, VPF



Informations sur le produit

69525-1-Ig cible VEGF165 dans les applications de Non-Neutralization et montre une réactivité avec des échantillons Humain

Réactivité Humain
Hôte / Isotype Mouse / IgG1
Clonalité Monoclonal
Type Anticorps
Immunogène human Humankine VEGF165 protein HZ-1038
Nom complet vascular endothelial growth factor A
Symbole du gène VEGFA
Identification du gène (NCBI) 7422
Conjugaison Non conjugué
Forme Lyophilized Powder
Méthode de purification Purification par protéine G
Tampon de stockage PBS stérile.
Endotoxin<0.1 EU/μg
ReconstitutionThis product was lyophilized from a 0.2 μm filtered solution in PBS. Reconstitute at 1.0 mg/mL in sterile H2O before use.
Stability and StorageLyophilized antibodies are stable for 1 year from the date of receipt if stored between (-20°C) and (-80°C). Upon reconstitution we recommend that the solution can be stored at (4°C) for short term or at (-20°C) to (-80°C) for long term. Repeated freeze thaw cycles should be avoided with reconstituted products.

Informations générales

VEGFA, also named as VEGF or VPF, belongs to the PDGF/VEGF growth factor family. It is a growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. VEGFA induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. It binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. Defects in VEGFA are associated with microvascular complications of diabetes type 1 (MVCD1). VEGFA has 17 isoforms with MW from 16 to 45 kDa. Some isoforms have homodimer forms (e.g.; VEGFA189 38 kDa or VEFGA110 34 kDa). VEGF-A exists in at least seven homodimeric isoforms. The monomers consist of 121, 145, 148, 165, 183, 189, or 206 amino acids (PMID:15602010 ).

This antibody is a neutralizing control antibody for VEGF165, the immunogen is the same as Neutrakine 69025-1-Ig but could not neutralize human VEGF165.